sirolimus Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
immunosuppressants, rapamycin derivatives 2446 53123-88-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sirolimus
  • rapamycin
  • rapammune
  • rapamune
  • supralimus
  • rapalimus
  • AY22989
  • AY-22989
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. Limited data describing efficacy in patients with COVID-19 is available. However, its efficacy and safety in the treatment of COVID-19 was not established.
  • Molecular weight: 914.19
  • Formula: C51H79NO13
  • CLOGP: 7.04
  • LIPINSKI: 3
  • HAC: 14
  • HDO: 3
  • TPSA: 195.43
  • ALOGS: -5.72
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.15 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Sept. 15, 1999 FDA PF PRISM CV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Transplant dysfunction 2024.93 18.20 435 15017 4247 46666363
Transplant rejection 1919.14 18.20 476 14976 9120 46661490
Ovarian cyst 1403.98 18.20 403 15049 13684 46656926
Acne 1249.72 18.20 399 15053 19520 46651090
Sleep disorder due to general medical condition, insomnia type 575.28 18.20 162 15290 5087 46665523
Alopecia 552.20 18.20 444 15008 161970 46508640
Product use in unapproved indication 270.60 18.20 230 15222 90043 46580567
Liver function test abnormal 216.75 18.20 154 15298 46333 46624277
Epstein-Barr virus infection 176.62 18.20 71 15381 6713 46663897
Post transplant lymphoproliferative disorder 168.57 18.20 59 15393 3797 46666813
Kidney transplant rejection 164.78 18.20 59 15393 4059 46666551
Thrombotic microangiopathy 162.75 18.20 71 15381 8235 46662375
Product use issue 131.15 18.20 159 15293 94485 46576125
Kidney fibrosis 120.57 18.20 36 15416 1389 46669221
Condition aggravated 115.74 18.20 252 15200 244800 46425810
Immunosuppressant drug level increased 112.65 18.20 42 15410 3240 46667370
Graft versus host disease 112.02 18.20 51 15401 6537 46664073
Off label use 104.04 18.20 318 15134 379523 46291087
Pneumonia 99.28 18.20 311 15141 376009 46294601
Liver transplant rejection 95.97 18.20 30 15422 1353 46669257
Epstein-Barr virus associated lymphoproliferative disorder 89.88 18.20 29 15423 1450 46669160
Polyomavirus-associated nephropathy 77.61 18.20 26 15426 1464 46669146
Human herpesvirus 6 infection 72.13 18.20 28 15424 2411 46668199
Chronic allograft nephropathy 70.63 18.20 20 15432 638 46669972
Smooth muscle cell neoplasm 69.07 18.20 19 15433 544 46670066
Loss of personal independence in daily activities 67.87 18.20 89 15363 57094 46613516
Graft versus host disease in gastrointestinal tract 67.43 18.20 27 15425 2523 46668087
Cytomegalovirus infection 64.17 18.20 51 15401 18093 46652517
Cryptosporidiosis infection 61.94 18.20 15 15437 255 46670355
MELAS syndrome 56.48 18.20 12 15440 109 46670501
Renal graft infection 56.28 18.20 12 15440 111 46670499
BK virus infection 54.64 18.20 24 15428 2825 46667785
JC virus infection 52.43 18.20 20 15432 1642 46668968
Skin squamous cell carcinoma metastatic 51.64 18.20 8 15444 6 46670604
Alveolar proteinosis 49.56 18.20 13 15439 309 46670301
Graft versus host disease in skin 48.86 18.20 21 15431 2346 46668264
Heart transplant rejection 48.75 18.20 14 15438 470 46670140
Arthralgia 47.80 18.20 31 15421 364572 46306038
Nephropathy toxic 47.44 18.20 30 15422 7424 46663186
Blood creatinine increased 43.45 18.20 85 15367 76318 46594292
Fall 43.10 18.20 28 15424 329069 46341541
Posterior reversible encephalopathy syndrome 42.02 18.20 37 15415 15104 46655506
Incorrect route of product administration 41.45 18.20 38 15414 16345 46654265
Renal impairment 41.40 18.20 82 15370 74290 46596320
Drug level increased 41.34 18.20 40 15412 18401 46652209
Pneumonitis 41.33 18.20 49 15403 28371 46642239
Lymphocele 41.18 18.20 14 15438 824 46669786
Globulins decreased 39.53 18.20 10 15442 205 46670405
Rash 39.48 18.20 36 15416 356476 46314134
Adenovirus infection 39.14 18.20 19 15433 2811 46667799
Rheumatoid arthritis 38.21 18.20 169 15283 240046 46430564
Pancreas transplant rejection 38.16 18.20 9 15443 136 46670474
Pseudomonas infection 37.90 18.20 29 15423 9729 46660881
Neurofibrosarcoma 37.73 18.20 9 15443 143 46670467
Drug level below therapeutic 37.28 18.20 19 15433 3118 46667492
Dizziness 36.95 18.20 35 15417 340379 46330231
Complications of transplanted kidney 36.84 18.20 17 15435 2246 46668364
Fatigue 36.18 18.20 94 15358 608603 46062007
Immunosuppressant drug level decreased 35.95 18.20 13 15439 919 46669691
Somnolence 35.19 18.20 5 15447 156516 46514094
Adjusted calcium decreased 34.89 18.20 8 15444 106 46670504
Avian influenza 34.31 18.20 7 15445 51 46670559
Focal segmental glomerulosclerosis 33.98 18.20 14 15438 1407 46669203
Chronic graft versus host disease 33.83 18.20 17 15435 2708 46667902
Proteinuria 33.57 18.20 34 15418 16519 46654091
Polyomavirus viraemia 33.56 18.20 10 15442 383 46670227
Cytomegalovirus infection reactivation 33.51 18.20 14 15438 1458 46669152
Bacillary angiomatosis 31.81 18.20 7 15445 76 46670534
Bronchiolitis obliterans syndrome 31.02 18.20 7 15445 86 46670524
Drug hypersensitivity 30.22 18.20 22 15430 243803 46426807
Acute graft versus host disease 30.18 18.20 18 15434 4012 46666598
Jejunal perforation 30.17 18.20 7 15445 98 46670512
Alopecia scarring 29.73 18.20 7 15445 105 46670505
Endocarditis Q fever 29.58 18.20 5 15447 10 46670600
Hypertriglyceridaemia 29.10 18.20 20 15432 5684 46664926
Chronic graft versus host disease in skin 29.04 18.20 10 15442 612 46669998
Hepatitis E 28.93 18.20 12 15440 1227 46669383
Pain in extremity 28.75 18.20 26 15426 258654 46411956
Back pain 28.67 18.20 17 15435 210022 46460588
Trichostasis spinulosa 28.14 18.20 5 15447 15 46670595
Drug interaction 27.93 18.20 137 15315 202957 46467653
Jarisch-Herxheimer reaction 26.90 18.20 8 15444 304 46670306
Constipation 26.86 18.20 12 15440 174085 46496525
Skin graft rejection 26.83 18.20 5 15447 21 46670589
Hypoalbuminaemia 26.61 18.20 24 15428 10103 46660507
Haemodialysis 26.53 18.20 23 15429 9194 46661416
Joint swelling 26.33 18.20 11 15441 166062 46504548
Graft thrombosis 26.20 18.20 7 15445 179 46670431
Dyspnoea 25.94 18.20 86 15366 515462 46155148
Anxiety 25.87 18.20 14 15438 181943 46488667
Squamous cell carcinoma 25.53 18.20 21 15431 7815 46662795
Hypersensitivity 25.42 18.20 9 15443 150312 46520298
Product dose omission issue 25.40 18.20 12 15440 168508 46502102
Muscle spasms 25.30 18.20 5 15447 123108 46547502
Pneumocystis jirovecii pneumonia 25.04 18.20 28 15424 15220 46655390
Pruritus 25.02 18.20 26 15426 242326 46428284
Lymphopenia 24.97 18.20 28 15424 15265 46655345
Drug level fluctuating 24.87 18.20 8 15444 396 46670214
Nausea 24.51 18.20 131 15321 687323 45983287
Fibrosarcoma 24.39 18.20 4 15448 6 46670604
Hepatic fibrosis 24.07 18.20 14 15438 2981 46667629
Gait disturbance 24.05 18.20 9 15443 145254 46525356
Disseminated mycobacterium avium complex infection 23.88 18.20 5 15447 42 46670568
Feeling abnormal 23.85 18.20 6 15446 125054 46545556
Overdose 23.73 18.20 81 15371 101898 46568712
Haemolytic uraemic syndrome 23.57 18.20 13 15439 2501 46668109
Renal tubular necrosis 23.48 18.20 23 15429 10736 46659874
Morphoea 22.78 18.20 7 15445 298 46670312
Kussmaul respiration 22.47 18.20 6 15446 153 46670457
Transplant failure 22.24 18.20 10 15442 1244 46669366
Pulmonary alveolar haemorrhage 22.20 18.20 15 15437 4147 46666463
Bacterial colitis 22.19 18.20 5 15447 61 46670549
Cat scratch disease 22.04 18.20 6 15446 165 46670445
Pterygium 21.87 18.20 6 15446 170 46670440
Multiple organ dysfunction syndrome 21.84 18.20 51 15401 51659 46618951
Obliterative bronchiolitis 21.82 18.20 11 15441 1764 46668846
Q fever 21.76 18.20 5 15447 67 46670543
Chest pain 21.71 18.20 16 15436 176308 46494302
Insomnia 21.59 18.20 14 15438 164910 46505700
Enterovirus infection 21.59 18.20 8 15444 606 46670004
Rhinovirus infection 21.56 18.20 14 15438 3622 46666988
Acute graft versus host disease in skin 21.51 18.20 13 15439 2969 46667641
Interstitial lung disease 21.48 18.20 52 15400 53897 46616713
Aspergillus infection 21.48 18.20 18 15434 6872 46663738
Headache 21.26 18.20 84 15368 478268 46192342
Human herpesvirus 8 infection 21.14 18.20 6 15446 193 46670417
Respiratory failure 20.92 18.20 74 15378 94742 46575868
Salivary gland mass 20.82 18.20 5 15447 82 46670528
Viraemia 20.77 18.20 9 15443 1025 46669585
Malaise 20.49 18.20 50 15402 331182 46339428
Bacterial translocation 20.41 18.20 6 15446 219 46670391
Acute hepatitis C 20.38 18.20 5 15447 90 46670520
Septic shock 20.12 18.20 53 15399 57840 46612770
Syncope 20.03 18.20 5 15447 104798 46565812
Klebsiella infection 19.94 18.20 17 15435 6645 46663965
White matter lesion 19.92 18.20 9 15443 1132 46669478
Lung transplant rejection 19.84 18.20 8 15444 761 46669849
Thymus enlargement 19.83 18.20 5 15447 101 46670509
Pulmonary artery atresia 19.51 18.20 4 15448 30 46670580
Loss of consciousness 19.13 18.20 6 15446 108232 46562378
Renal transplant 18.77 18.20 9 15443 1296 46669314
Diabetes mellitus 18.60 18.20 47 15405 50018 46620592
Pleural effusion 18.52 18.20 65 15387 82887 46587723
Cardiac murmur functional 18.48 18.20 4 15448 40 46670570
Neonatal seizure 18.42 18.20 6 15446 309 46670301
Sinusitis 18.41 18.20 10 15442 129758 46540852
Bronchopulmonary aspergillosis 18.21 18.20 17 15435 7479 46663131

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product use in unapproved indication 422.48 14.22 337 16001 73356 29862784
Transplant rejection 351.63 14.22 146 16192 9060 29927080
Kidney transplant rejection 306.84 14.22 125 16213 7384 29928756
Off label use 289.83 14.22 499 15839 248791 29687349
Post transplant lymphoproliferative disorder 149.69 14.22 68 16270 5238 29930902
Liver transplant rejection 126.69 14.22 47 16291 2151 29933989
Immunosuppressant drug level increased 116.25 14.22 55 16283 4647 29931493
Cytomegalovirus infection 103.72 14.22 93 16245 23581 29912559
Thrombotic microangiopathy 102.78 14.22 62 16276 8548 29927592
Adenovirus infection 102.69 14.22 49 16289 4219 29931921
Product use issue 97.88 14.22 123 16215 45893 29890247
BK virus infection 95.64 14.22 47 16291 4317 29931823
Acute graft versus host disease 85.27 14.22 48 16290 5816 29930324
Transplant failure 83.19 14.22 36 16302 2468 29933672
Nephropathy toxic 81.41 14.22 58 16280 10581 29925559
Chronic allograft nephropathy 78.63 14.22 28 16310 1138 29935002
Lymphocele 76.08 14.22 29 16309 1431 29934709
Complications of transplanted kidney 74.76 14.22 39 16299 4062 29932078
Graft versus host disease 74.60 14.22 54 16284 10096 29926044
Squamous cell carcinoma 74.13 14.22 54 16284 10196 29925944
Epstein-Barr virus infection 71.65 14.22 45 16293 6661 29929479
Blood creatinine increased 66.53 14.22 151 16187 91224 29844916
Chronic graft versus host disease 63.39 14.22 35 16303 4084 29932056
Meningitis viral 62.80 14.22 21 16317 705 29935435
Nocardiosis 60.54 14.22 32 16306 3423 29932717
Proteinuria 60.21 14.22 58 16280 16087 29920053
Cytomegalovirus viraemia 60.09 14.22 38 16300 5691 29930449
Propionibacterium infection 59.52 14.22 16 16322 248 29935892
Transplant dysfunction 53.53 14.22 26 16312 2326 29933814
Kidney fibrosis 53.41 14.22 25 16313 2060 29934080
Graft versus host disease in skin 53.37 14.22 29 16309 3278 29932862
Brain abscess 50.31 14.22 26 16312 2655 29933485
Bronchopulmonary aspergillosis 49.37 14.22 46 16292 12238 29923902
Squamous cell carcinoma of skin 46.41 14.22 39 16299 9056 29927084
Graft versus host disease in liver 45.46 14.22 18 16320 984 29935156
Impaired healing 45.15 14.22 47 16291 14293 29921847
Graft versus host disease in gastrointestinal tract 44.28 14.22 25 16313 3044 29933096
Interstitial lung disease 42.13 14.22 98 16240 60099 29876041
Heart transplant rejection 41.57 14.22 18 16320 1235 29934905
Renal impairment 41.36 14.22 120 16218 84064 29852076
Central nervous system lymphoma 40.59 14.22 16 16322 864 29935276
Diaphragmatic hernia 40.32 14.22 12 16326 273 29935867
Cow pox 39.67 14.22 8 16330 30 29936110
Pleocytosis 38.25 14.22 13 16325 459 29935681
Renal tubular atrophy 37.68 14.22 16 16322 1046 29935094
Dizziness 37.29 14.22 31 16307 194878 29741262
Herpes zoster meningoencephalitis 36.76 14.22 11 16327 255 29935885
Haemolytic uraemic syndrome 36.37 14.22 19 16319 1983 29934157
Acute graft versus host disease in skin 35.41 14.22 25 16313 4491 29931649
Constipation 35.36 14.22 9 16329 112897 29823243
Focal segmental glomerulosclerosis 35.09 14.22 18 16320 1809 29934331
Fatigue 34.21 14.22 78 16260 320595 29615545
Transitional cell carcinoma 33.60 14.22 18 16320 1977 29934163
Hepatic cancer recurrent 33.30 14.22 11 16327 355 29935785
Scedosporium infection 32.98 14.22 13 16325 702 29935438
Nephrogenic diabetes insipidus 32.72 14.22 15 16323 1178 29934962
Tularaemia 32.04 14.22 8 16330 91 29936049
Protothecosis 31.73 14.22 7 16331 44 29936096
Cytomegalovirus infection reactivation 30.37 14.22 16 16322 1699 29934441
Pharyngitis 30.18 14.22 27 16311 6815 29929325
Gastroenteritis norovirus 30.11 14.22 15 16323 1417 29934723
Human herpesvirus 8 infection 29.94 14.22 12 16326 677 29935463
Drug level decreased 29.84 14.22 25 16313 5780 29930360
Multiple organ dysfunction syndrome 29.73 14.22 89 16249 63398 29872742
Right ventricular diastolic collapse 29.13 14.22 7 16331 67 29936073
Enteritis 28.87 14.22 26 16312 6619 29929521
Anxiety 28.45 14.22 7 16331 89864 29846276
Diffuse large B-cell lymphoma 27.04 14.22 27 16311 7814 29928326
Renal tubular necrosis 26.56 14.22 37 16301 15214 29920926
Renal cancer stage I 25.91 14.22 5 16333 14 29936126
Hydronephrosis 25.72 14.22 28 16310 8955 29927185
Pneumonia cytomegaloviral 25.52 14.22 17 16321 2779 29933361
Malacoplakia 25.17 14.22 7 16331 124 29936016
Pericardial effusion 25.15 14.22 43 16295 21101 29915039
Ileal ulcer 24.90 14.22 10 16328 567 29935573
Drug effective for unapproved indication 24.56 14.22 12 16326 1087 29935053
Hypotension 24.55 14.22 45 16293 200520 29735620
Neuroendocrine carcinoma of the skin 24.29 14.22 10 16328 605 29935535
Venoocclusive disease 24.25 14.22 16 16322 2574 29933566
Normocytic anaemia 24.07 14.22 13 16325 1451 29934689
Diarrhoea haemorrhagic 23.82 14.22 22 16316 5783 29930357
Mouth ulceration 23.54 14.22 29 16309 10580 29925560
Drug interaction 23.23 14.22 187 16151 199381 29736759
Aspergillus infection 22.80 14.22 28 16310 10186 29925954
Drug level increased 22.72 14.22 38 16300 18316 29917824
Nail discolouration 22.11 14.22 10 16328 761 29935379
Smooth muscle cell neoplasm 22.03 14.22 6 16332 98 29936042
Escherichia infection 21.99 14.22 22 16316 6383 29929757
Pneumonitis 21.76 14.22 47 16291 27407 29908733
Hepatitis B 21.11 14.22 21 16317 6051 29930089
Bradycardia 20.94 14.22 5 16333 65521 29870619
Basal cell carcinoma 20.88 14.22 34 16304 16034 29920106
Varicella 20.83 14.22 12 16326 1518 29934622
Obliterative bronchiolitis 20.71 14.22 11 16327 1187 29934953
Cytomegalovirus colitis 20.60 14.22 14 16324 2365 29933775
Ureteric stenosis 20.43 14.22 11 16327 1220 29934920
Splenic neoplasm malignancy unspecified 20.28 14.22 4 16334 13 29936127
Hyperlipidaemia 20.24 14.22 31 16307 13876 29922264
Ophthalmic herpes zoster 20.23 14.22 9 16329 659 29935481
Escherichia urinary tract infection 20.18 14.22 15 16323 2917 29933223
Skin squamous cell carcinoma recurrent 20.05 14.22 4 16334 14 29936126
Scleroderma 19.66 14.22 11 16327 1316 29934824
Venoocclusive liver disease 19.61 14.22 21 16317 6592 29929548
Chronic graft versus host disease in skin 19.58 14.22 9 16329 711 29935429
Anuria 19.43 14.22 26 16312 10290 29925850
Abdominal wall abscess 19.38 14.22 8 16330 487 29935653
Plasma cell myeloma 19.36 14.22 3 16335 53459 29882681
Skin erosion 19.32 14.22 12 16326 1741 29934399
Livedo reticularis 19.16 14.22 13 16325 2191 29933949
Alternaria infection 19.08 14.22 7 16331 310 29935830
Polyomavirus-associated nephropathy 19.08 14.22 15 16323 3170 29932970
Depression 19.03 14.22 13 16325 90424 29845716
Bacterial sepsis 18.93 14.22 18 16320 4908 29931232
Insomnia 18.88 14.22 14 16324 93322 29842818
Cytomegalovirus chorioretinitis 18.74 14.22 15 16323 3253 29932887
Perinephric collection 18.71 14.22 6 16332 176 29935964
Microangiopathy 18.68 14.22 9 16329 791 29935349
Spirochaetal infection 18.58 14.22 4 16334 22 29936118
Wound dehiscence 18.45 14.22 15 16323 3326 29932814
Pulmonary toxicity 18.31 14.22 17 16321 4499 29931641
Syncope 18.14 14.22 12 16326 84891 29851249
Acute graft versus host disease in intestine 18.13 14.22 13 16325 2392 29933748
Acne 18.11 14.22 24 16314 9412 29926728
Posterior reversible encephalopathy syndrome 18.04 14.22 23 16315 8684 29927456
Pyrexia 18.01 14.22 242 16096 294247 29641893
Lactobacillus infection 17.95 14.22 5 16333 89 29936051
Candida infection 17.95 14.22 31 16307 15331 29920809
Somnolence 17.73 14.22 16 16322 96747 29839393
Immunosuppressant drug level decreased 17.47 14.22 10 16328 1249 29934891
Varicella zoster virus infection 17.41 14.22 10 16328 1258 29934882
Macroglossia 17.36 14.22 6 16332 223 29935917
Human polyomavirus infection 17.29 14.22 8 16330 642 29935498
Stem cell transplant 17.18 14.22 12 16326 2119 29934021
Drug ineffective for unapproved indication 16.90 14.22 25 16313 10855 29925285
Complications of transplanted heart 16.89 14.22 6 16332 242 29935898
Osmotic demyelination syndrome 16.88 14.22 8 16330 678 29935462
Pneumocystis jirovecii infection 16.86 14.22 10 16328 1335 29934805
Pruritus 16.81 14.22 24 16314 118180 29817960
Herpes simplex 16.56 14.22 16 16322 4448 29931692
Back pain 16.48 14.22 19 16319 102577 29833563
Pulmonary cavitation 16.44 14.22 8 16330 718 29935422
Fall 16.44 14.22 48 16290 181824 29754316
Arthralgia 16.13 14.22 31 16307 135760 29800380
Urticaria 15.88 14.22 5 16333 54601 29881539
Chronic obstructive pulmonary disease 15.80 14.22 3 16335 46123 29890017
Bladder transitional cell carcinoma 15.67 14.22 12 16326 2441 29933699
Microvillous inclusion disease 15.60 14.22 4 16334 51 29936089
Pathogen resistance 15.54 14.22 21 16317 8389 29927751
Muscle spasms 15.50 14.22 8 16330 64830 29871310
Haemorrhagic pneumonia 15.45 14.22 5 16333 151 29935989
Pyelonephritis acute 15.30 14.22 10 16328 1583 29934557
Pneumonia adenoviral 15.24 14.22 5 16333 158 29935982
Hyperhidrosis 14.99 14.22 9 16329 67081 29869059
Peritoneal hernia 14.72 14.22 3 16335 12 29936128
Rabies 14.72 14.22 3 16335 12 29936128
Ovarian cyst 14.72 14.22 3 16335 12 29936128
Pneumatosis intestinalis 14.69 14.22 12 16326 2678 29933462
Epstein-Barr viraemia 14.69 14.22 8 16330 908 29935232
Cachexia 14.55 14.22 18 16320 6593 29929547
Disease recurrence 14.53 14.22 27 16311 14134 29922006
Rhinitis 14.45 14.22 15 16323 4544 29931596
Nausea 14.36 14.22 99 16239 296858 29639282
Overdose 14.22 14.22 15 16323 84322 29851818

Pharmacologic Action:

SourceCodeDescription
ATC L04AA10 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
ATC S01XA23 SENSORY ORGANS
OPHTHALMOLOGICALS
OTHER OPHTHALMOLOGICALS
Other ophthalmologicals
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA PE N0000175550 Decreased Immunologic Activity
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000175624 mTOR Inhibitors
FDA EPC N0000175625 mTOR Inhibitor Immunosuppressant
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000935 Antifungal Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:35705 immunosuppressant
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:68481 mammalian target of rapamycin inhibitor
CHEBI has role CHEBI:149553 anti-coronaviral agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pulmonary lymphangioleiomyomatosis indication 277844007 DOID:3319
Renal cell carcinoma indication 702391001 DOID:4450
Prevention of Kidney Transplant Rejection indication
Coronavirus infection off-label use 186747009
Prevention of Cardiac Transplant Rejection off-label use
Hypercholesterolemia contraindication 13644009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Transplantation of liver contraindication 18027006
Progressive multifocal leukoencephalopathy contraindication 22255007 DOID:643
Cytomegalovirus infection contraindication 28944009
Proteinuria contraindication 29738008 DOID:576
Hypertensive disorder contraindication 38341003 DOID:10763
Infectious disease contraindication 40733004
Body fluid retention contraindication 43498006
Gastrointestinal perforation contraindication 51875005
Hyperlipidemia contraindication 55822004 DOID:1168
Acute infectious disease contraindication 63171007
Interstitial pneumonia contraindication 64667001
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Transplant of lung contraindication 88039007
Kidney disease contraindication 90708001 DOID:557
Secondary malignant neoplasm of cerebrum contraindication 94248000
Malignant lymphoma contraindication 118600007 DOID:0060058
Perioperative care contraindication 133897009
Cerebrovascular accident contraindication 230690007
Interstitial lung disease contraindication 233703007 DOID:3082
Lymphedema contraindication 234097001 DOID:4977
Disease of liver contraindication 235856003 DOID:409
Impaired wound healing contraindication 271618001
Peripheral edema contraindication 271809000
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Primary malignant neoplasm contraindication 372087000
Malignant neoplasm of skin contraindication 372130007 DOID:4159
Pericardial effusion contraindication 373945007 DOID:118
Surgical procedure contraindication 387713003
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Pneumocystosis jiroveci pneumonia contraindication 415125002 DOID:11339
Malignant neoplasm of brain contraindication 428061005 DOID:1319
Bronchial Anastomotic Dehiscence in Lung Transplant contraindication
BK Polyomavirus Reactivation Nephropathy contraindication
Sirolimus Toxicity contraindication
Hepatic Artery Thrombosis in Liver Transplant contraindication
Pleural Effusions contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.5 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1MG/ML RAPAMUNE PF PRISM CV N021083 Sept. 15, 1999 RX SOLUTION ORAL May 28, 2022 TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
0.5MG RAPAMUNE PF PRISM CV N021110 Jan. 25, 2010 RX TABLET ORAL May 28, 2022 TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
1MG RAPAMUNE PF PRISM CV N021110 Aug. 25, 2000 RX TABLET ORAL May 28, 2022 TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
2MG RAPAMUNE PF PRISM CV N021110 Aug. 22, 2002 RX TABLET ORAL May 28, 2022 TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** RAPAMUNE PF PRISM CV N021110 Feb. 23, 2004 DISCN TABLET ORAL May 28, 2022 TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Peptidyl-prolyl cis-trans isomerase FKBP1A Enzyme INHIBITOR Kd 8.96 WOMBAT-PK CHEMBL
Cytochrome P450 3A4 Enzyme IC50 5.70 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 5.70 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 5.40 DRUG MATRIX
Sodium/nucleoside cotransporter 1 Transporter Ki 6.43 DRUG MATRIX
Peptidyl-prolyl cis-trans isomerase FKBP3 Enzyme Kd 9.70 WOMBAT-PK
Multidrug resistance protein 1 Transporter IC50 6.20 WOMBAT-PK
Serine/threonine-protein kinase mTOR Kinase IC50 10 CHEMBL
Eukaryotic translation initiation factor 4E Nuclear other Kd 9.30 CHEMBL
Programmed cell death protein 4 Unclassified EC50 7.30 CHEMBL
Peptidyl-prolyl cis-trans isomerase FKBP5 Enzyme Ki 8.52 CHEMBL
Peptidyl-prolyl cis-trans isomerase FKBP1B Enzyme Kd 9.70 CHEMBL

External reference:

IDSource
4021176 VUID
N0000148624 NUI
D00753 KEGG_DRUG
4021176 VANDF
C0878382 UMLSCUI
CHEBI:9168 CHEBI
CHEMBL413 ChEMBL_ID
5284616 PUBCHEM_CID
D020123 MESH_DESCRIPTOR_UI
DB00877 DRUGBANK_ID
6031 IUPHAR_LIGAND_ID
7104 INN_ID
W36ZG6FT64 UNII
258355 RXNORM
210889 MMSL
31418 MMSL
8303 MMSL
d04453 MMSL
007885 NDDF
116109004 SNOMEDCT_US
387014003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rapamune HUMAN PRESCRIPTION DRUG LABEL 1 0008-1030 SOLUTION 1 mg ORAL NDA 34 sections
Rapamune HUMAN PRESCRIPTION DRUG LABEL 1 0008-1040 TABLET, SUGAR COATED 0.50 mg ORAL NDA 34 sections
Rapamune HUMAN PRESCRIPTION DRUG LABEL 1 0008-1041 TABLET, SUGAR COATED 1 mg ORAL NDA 34 sections
Rapamune HUMAN PRESCRIPTION DRUG LABEL 1 0008-1042 TABLET, SUGAR COATED 2 mg ORAL NDA 34 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 50268-718 TABLET 1 mg ORAL ANDA 29 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 55111-653 TABLET 1 mg ORAL ANDA 28 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 55111-654 TABLET 2 mg ORAL ANDA 28 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 59762-1001 TABLET, SUGAR COATED 0.50 mg ORAL NDA AUTHORIZED GENERIC 31 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 59762-1002 TABLET, SUGAR COATED 1 mg ORAL NDA AUTHORIZED GENERIC 31 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 59762-1003 TABLET, SUGAR COATED 2 mg ORAL NDA AUTHORIZED GENERIC 31 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 59762-1205 SOLUTION 1 mg ORAL NDA AUTHORIZED GENERIC 34 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 60505-6197 SOLUTION 1 mg ORAL ANDA 31 sections
sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 65841-771 TABLET, FILM COATED 0.50 mg ORAL ANDA 1 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 66689-347 SOLUTION 1 mg ORAL ANDA 29 sections
Sirolimus Human Prescription Drug Label 1 67877-746 TABLET 0.50 mg ORAL ANDA 29 sections
Sirolimus Human Prescription Drug Label 1 67877-747 TABLET 1 mg ORAL ANDA 29 sections
Sirolimus Human Prescription Drug Label 1 67877-748 TABLET 2 mg ORAL ANDA 29 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 68084-915 TABLET 1 mg ORAL ANDA 30 sections
sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 68382-520 TABLET, FILM COATED 0.50 mg ORAL ANDA 27 sections
sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 68462-682 TABLET, FILM COATED 0.50 mg ORAL ANDA 29 sections
sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 68462-683 TABLET, FILM COATED 1 mg ORAL ANDA 29 sections
sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 68462-684 TABLET, FILM COATED 2 mg ORAL ANDA 29 sections
Sirolimus HUMAN PRESCRIPTION DRUG LABEL 1 69238-1594 SOLUTION 1 mg ORAL ANDA 30 sections